Pre-announcements: 

Breast Cancer Research Program

• Breakthrough Award Levels 1 and 2

• Clinical Research Extension Award

Applications submitted to the FY26 BCRP must address one or more of the following overarching challenges:

• Prevent breast cancer (primary prevention)

• Identify determinants of breast cancer initiation, risk or susceptibility

• Distinguish deadly from non-deadly breast cancers

• Conquer the problems of overdiagnosis and overtreatment

• Identify what drives breast cancer growth; determine how to stop it

• Identify why some breast cancers become metastatic

• Determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence

• Revolutionize treatment regimens by replacing them with ones that do all the following: improve survival, are more effective and are less toxic

• Eliminate the mortality associated with metastatic breast cancer

Reconstructive Transplant Research Program

• Investigator-Initiated Research Award

Applications submitted to the FY26 RTRP must address one or more of the following focus areas:

• Improve or optimize VCA immunosuppression

  • Define the unique targets and/or mechanisms of VCA immunogenicity and its regulation

  • Develop novel tolerogenic agents or approaches for VCA immunosuppression

  • Develop less toxic and/or personalized regimens for maintenance immunosuppression

• Identify and/or validate reliable prognostic or diagnostic biomarkers, methods, or tools for monitoring the specific needs of VCA graft rejection and immunosuppression

  • Identify and/or validate reliable biomarkers for predicting and monitoring acute and chronic VCA rejection in the clinic, i.e., human clinical samples

  • Develop assays, devices or technology for clinical graft monitoring utilizing biomarkers; proposed devices should consider human use factors unique to VCA recipients

  • Identify and/or validate reliable approaches to measuring and monitoring in vivo or clinical immunosuppression levels

• Advance VCA preservation strategies

  • Develop promising static preservation strategies, active perfusion modalities or other technologies for translation to the clinic

  • Develop mitigation strategies for preservation-mediated injury, including immune activation or ischemia reperfusion injury

• Develop tools for measuring VCA outcomes including

  • Performance (functional)-based

  • Patient-reported

  • Neurocognitive

Pre-Solicitation Notice – Threat-Agnostic CBRN TherapeutICs (TACTIC)

Medical countermeasures (MCMs) for chemical, biological, radiological, and nuclear (CBRN) threats have historically relied on agent-specific therapeutics that require rapid identification of the causative agent and early administration to achieve clinical benefit. While effective in defined scenarios, this approach presents a significant capability gap when diagnosis is delayed or infeasible, countermeasures are unavailable, or patients present during later stages of disease when direct-acting therapeutics are less effective.

To address this capability gap, BARDA seeks to support the development of therapeutics that treat host-dysregulation resulting from exposure to priority threats. Such therapeutics can be deployed independent of threat identification and retain clinical effectiveness in delayed treatment settings. Such therapeutics are intended to preserve or restore physiological function, mitigate systemic injury, and improve clinical outcomes by targeting host responses rather than specific threat agents. Products with the potential for broad applicability across multiple CBRN threat categories are of particular interest.

Fast Assessment of Solutions, Therapeutics, Pharmaceuticals, and Supplies - (FASTPASS)

Proposers' Day

This second hybrid event will provide additional information and clarify processes for potential proposers.

It is recommended that potential performers attend both events to improve opportunities for interaction and teaming.

• Event date: September 10, 2026 
• Registration: Required by September 4, 2026 (12:00 PM ET)
• Event location: Hybrid in Arlington, VA
• Full Details: See the Special Notice ARPA-H-SN-26-160 on SAM.gov for full event information.

Systems for Tracking and Resilience in Efficient Agricultural-input Management – (STREAM) 

Request for Project Information: Military Injury Cause Coding

MTEC has issued a Request for Project Information (RPI) focused on surveying the current state of developing, testing, and implementing artificial intelligence (AI)-driven processes aimed at improving electronic health record (EHR) injury cause coding without overburdening those responsible for documenting military injuries. The information gathered by this RPI will be shared with relevant interested government parties to help inform future development and procurement efforts.

Medical Extraction BAA – Quad Chart and White Paper due by December 31, 2026 

Medical Future Capability Directorate (MED FCD) is seeking proposals for innovative technological capabilities to facilitate medical extractions in highly contested environments where maintaining a low operational profile is critical. Proposed solutions must be capable of retrieving and securing ambulatory and non-ambulatory casualties who are unable to climb or physically assist in their own loading, thereby minimizing the exposure of accompanying rescue personnel. Furthermore, the system must demonstrate high mobility to successfully traverse rugged, unstructured terrain while maintaining rigorous patient stabilization, ensuring that the extraction and transport process inflicts no further harm to the casualty.

The National Institute of General Medical Sciences (NIGMS) is hosting an informational webinar for small businesses interested in applying for NIH Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) funding opportunities.

Key Details:

• Date: October 26, 2026
• Time: 1:00 PM to 2:00 PM ET
• Format: Microsoft Teams webinar
• Topic: Overview of the NIGMS Small Business Program, including guidance on applying to: 
  • Parent SBIR (R43/R44) Clinical Trial Optional funding opportunity (PA-27-100)
  • Parent STTR (R41/R42) Clinical Trial Optional funding opportunity (PA-27-102)

The National Institute of General Medical Sciences (NIGMS) is hosting an informational webinar for organizations interested in applying to PAR-27-054, “Centers of Biomedical Research Excellence: Development Phase (COBRE-D) (P30 - Clinical Trial Not Allowed).” The webinar is intended to provide a program overview and answer questions from prospective applicants.

Key Details:

• Date: Wednesday, September 9, 2026
• Time: 3:00 PM to 4:30 PM ET 
• Format: Microsoft Teams webinar 
• Funding Opportunity: PAR-27-054

AI-Based Remote Operation and Adaptive Modeling for Chemical and Biological (CB) Sensors – Draft SOO

The purpose of this Other Transaction Authority is to design, develop, and demonstrate an Artificial Intelligence (AI) and Machine Learning (ML) based approach for the remote operation, health monitoring, and adaptive optimization of fielded Chemical and Biological (CB) sensors. This project establishes a focused, high-impact initiative to create a modular AI Model Suite. Deployed at the tactical edge and supported by a centralized cloud or server architecture, this suite will maximize the reliability, performance, and life cycle of CB sensors in contested environments.

PCORI FY26 Research Project Agenda Topic Themes